Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 11/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 3/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21586529 | 0.95 | MAPT (0.43) | MAPTNLRP3MEN1KMT2ALMNA | |
| SCHEMBL19272170 | 0.90 | MEN1 (0.41) | MAPTNLRP3MEN1KMT2ALMNA | |
| SCHEMBL21892900 | 0.89 | DRD2 (0.31) | DRD4DRD2 | |
| SCHEMBL4888772 | 0.80 | MAPT (0.37) | MAPTNLRP3MEN1KMT2ALMNA | |
| SCHEMBL22280260 | 0.78 | MEN1 (0.41) | NLRP3MEN1KMT2AALDH1A1 | |
| SCHEMBL20681022 | 0.75 | ACHE (0.39) | MAPTNLRP3MEN1KMT2ALMNA | |
| SCHEMBL30042078 | 0.75 | NLRP3 (0.36) | MAPTNLRP3LMNAATMSMN1; SMN2 | |
| SCHEMBL30498486 | 0.75 | ACHE (0.39) | MAPTNLRP3MEN1KMT2ALMNA | |
| SCHEMBL20681027 | 0.75 | MAPT (0.33) | MAPTNLRP3LMNAATMSMN1; SMN2 | |
| SCHEMBL24960169 | 0.75 | MAPT (0.45) | MAPTNLRP3LMNAATMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200087270-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087270-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MAPT 2020/4885NLRP3 2/4885MEN1 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.